Get started
Author

Hirotaka Mano

Observed name: Mano, Hirotaka
Institution: Kyowa Kirin (Japan)
Observed institution: Kyowa Kirin (Japan)
ORCID: 0000-0003-0103-7748
Observed ORCID: 0000-0003-0103-7748
OpenAlex ID: A5031032841
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
2022 · Emma Guttman-Yassky, Eric L Simpson, et al. · The Lancet · 196
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis
2025 · Emma Guttman-Yassky, Eric Simpson, et al. · Immunotherapy · 21
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab
2024 · Emma Guttman-Yassky, Ehsanollah Esfandiari, et al. · Archives of Dermatological Research · 12
PDF
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis
2025 · Emma Guttman-Yassky, Eric Simpson, et al. · Dermatology and Therapy · 9
PDF
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
2024 · Emma Guttman-Yassky, Eric L. Simpson, et al. · Advances in Therapy · 7
PDF
Application of sample size re-estimation in clinical trials: A systematic review
2023 · Hirotaka Mano, Yuji Tanaka, et al. · Contemporary Clinical Trials Communications · 7
50233 Rocatinlimab Significantly Improves Clinical Responses in Patients with Moderate-To-Severe Atopic Dermatitis by Week 2 in a Randomized Double-Blind Placebo-Controlled Phase 2b Study
2024 · Emma Guttman-Yassky, Ehsanollah Esfandiari, et al. · Journal of the American Academy of Dermatology · 2
679 - Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
2024 · Emma Guttman-Yassky, Ehsanollah Esfandiari, et al. · British Journal of Dermatology · 1
Adjusting confidence intervals under covariate-adaptive randomization in non-inferiority and equivalence trials
2025 · Masahiro Kojima, Hirotaka Mano, et al. · Contemporary Clinical Trials
PDF
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis – Authors' reply
2023 · Emma Guttman-Yassky, Eric L Simpson, et al. · The Lancet
PDF
Works count: 11
Citation count: 255
H-index: 6
I10-index: 3
Year
Topic
Type